The Past, Present, and Future of Personalized Medicine: Keynote Reflections from Scott Gottlieb, Senior Fellow at the American Enterprise Institute
On the morning of November 30, Scott Gottlieb will take the stage to kick off the conference with an opening keynote statement on “The Past, Present, and Future of Personalized Medicine.”
Few people are in a better position than Gottlieb to deliver informed and publicly impactful remarks on the trajectory of personalized medicine over the course of the last two decades.
When researchers completed the first sequencing of a human genome in 2003, a 30-year-old Gottlieb was already serving as a senior advisor to the commissioner of the United States Food and Drug Administration (FDA).
By the time Gottlieb became FDA’s 23rd commissioner in May of 2017, the number of personalized medicines on the market had grown to almost 150, up from just five in 2008. Despite a challenging political environment and two government lockdowns, Gottlieb spearheaded record numbers of additional personalized medicine approvals before stepping down as commissioner in April of 2019.
And when the COVID-19 pandemic reshaped the activities of health systems across the globe in 2020, Gottlieb joined the Personalized Medicine Coalition (PMC) to help define thinking about the future of the pandemic and personalized medicine during a virtual seminar titled COVID-19 and Personalized Medicine: Current Status and Lessons Learned. By then, he had become a household name for millions of Americans who recognize his capacity for delivering evidence-based policy counsel on the most pressing issues in health and medicine.
PMC Vice Chairperson Lauren Silvis, who served as Gottlieb’s chief of staff during his tenure as FDA commissioner, will introduce him to the conference audience.